Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Bochner on Molecular Profiling in Bladder Cancer

March 22nd 2019

Bernard H. Bochner, MD, FACS, chair of surgery, Memorial Sloan Kettering Cancer Center, discusses the importance of molecular profiling in the treatment of patients with bladder cancer.

Sznol Highlights Immunotherapy Advances in RCC

March 20th 2019

Mario Sznol, MD, highlights recent advances made with immunotherapy in renal cell carcinoma and sheds light on what the future may hold.

Pembrolizumab/Axitinib Favored as Frontline Standard in mRCC

March 20th 2019

Thomas Powles, MBBS, MRCP, MD, highlights key takeaways from pivotal trials and discusses how they impact the ever-changing landscape of metastatic renal cell carcinoma.

Dr. George on Dosing TKIs in RCC

March 20th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses the importance of dosing TKIs properly in patients with renal cell carcinoma (RCC).

Atezolizumab Shows Comparable Real-World Tolerability, Efficacy in Urothelial Carcinoma

March 19th 2019

Atezolizumab (Tecentriq) demonstrated consistent safety and efficacy with prior studies of the PD-L1 inhibitor in patients with locally advanced or metastatic urothelial carcinoma, including clinically relevant subgroups reflective of real-world clinical practice.

Dr. Shuch on Role of Cytoreductive Nephrectomy in RCC

March 19th 2019

Brian M. Shuch, MD, director of the Kidney Cancer Program, Alvin & Carrie Meinhardt Endowed Chair of Kidney Cancer Research, University of California, Los Angeles Institute of Urologic Oncology, discussed the role of cytoreductive nephrectomy in renal cell carcinoma.

Rini Discusses Future of Tivozanib, TKI/Immunotherapy Combos in mRCC

March 19th 2019

Brian I. Rini, MD, discusses the next steps with tivozanib (Fotivda) and immunotherapy/TKI combinations in patients with metastatic renal cell carcinoma.

Dr. Powles on the Results of the KEYNOTE-426 Trial in mRCC

March 15th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the results of the KEYNOTE-426 trial in metastatic renal cell carcinoma (mRCC).

Toxicities Associated With VEGF TKIs and Checkpoint Inhibitors in mRCC

March 15th 2019

Heather Greene, a nurse practitioner at West Cancer Center, discusses the toxicities that are associated with VEGF TKIs and checkpoint inhibitors in metastatic renal cell carcinoma (mRCC).

Dr. McDermott on Single-Agent Versus Combination Immunotherapy in RCC

March 14th 2019

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses single-agent versus combination immunotherapy in the treatment of patients with renal cell carcinoma.

Dr. Agarwal on the Combination of Lenvatinib and Everolimus in mRCC

March 13th 2019

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses the combination of lenvatinib (Lenvima) and everolimus in the treatment of patients with metastatic renal cell carcinoma (mRCC).

Dr. Wright on Unmet Needs in Muscle-Invasive Bladder Cancer

March 12th 2019

Jonathan L. Wright, MD, MS, FACS, medical director of the University of Washington Medical Center Urology Clinic, associate professor of Urology at University of Washington, and affiliate investigator at the Fred Hutchinson Cancer Research Center, discusses unmet needs in muscle-invasive bladder cancer.

Dr. Powles on Rationale for KEYNOTE-426 in mRCC

March 11th 2019

Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses the rationale for the KEYNOTE-426 study in patients with metastatic renal cell carcinoma.

Pembrolizumab Plus Lenvatinib Elicits Responses in Urothelial Cancer

March 11th 2019

Combining lenvatinib and pembrolizumab led to a 25% overall response rate in patients with urothelial carcinoma and was associated with a manageable safety profile.

Dr. Grivas on Bladder Preservation in Localized Bladder Cancer

March 9th 2019

Petros Grivas, MD, PhD, director, University of Washington Medicine’s Genitourinary Cancers Program, associate professor, oncology, University of Washington, Seattle Cancer Care Alliance, discusses data on bladder preservation in patients with localized bladder cancer.

Dr. Meric-Bernstam on CB-839 Plus Cabozantinib in RCC

March 8th 2019

Funda Meric-Bernstam, MD, chair, Department of Investigational Cancer Therapeutics, medical director, Institute for Personalized Cancer Therapy, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses the combination of CB-839 plus cabozantinib in patients with renal cell carcinoma.

Dr. Pal on Molecular Signatures in Renal Cell Carcinoma

March 7th 2019

Sumanta Kumar Pal, MD, a medical oncologist at City of Hope, discusses the emergence of molecular signatures in patients with renal cell carcinoma (RCC).

Dr. Balar Discusses KEYNOTE-057 Study in NMIBC

March 6th 2019

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses findings from the KEYNOTE-057 study presented at the 2019 Genitourinary Cancers Symposium.

Sacituzumab Govitecan Shows Early Promise in Urothelial Carcinoma

March 5th 2019

Scott T. Tagawa, MD, discusses the potential of sacituzumab govitecan in advanced urothelial cancers and reflects on progress made in prostate cancer.

Dr. Rini Discusses Tivozanib in Advanced RCC

March 2nd 2019

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential for tivozanib in patients with advanced renal cell carcinoma.